An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic ER+, HER2- Breast Cancer

This study is testing a new experimental drug called IDE574 to see how well it works and how safe it is for treating certain advanced cancers. Researchers are exploring if this drug, either alone or combined with another therapy called fulvestrant, can help stop cancer cells from growing.

This trial is for adults with specific types of advanced solid tumors, including certain breast, lung, prostate, and colorectal cancers. Participants must have previously tried other standard treatments that are no longer working or were too difficult to tolerate, and they must have tumor tissue available for testing.

Participants will receive either the new drug alone or in combination with fulvestrant, depending on their specific cancer type. You will undergo regular check-ups, blood tests, and scans so the medical team can carefully monitor your health and how your body responds to the treatment.

This study is currently recruiting patients at medical centers in Plantation, Florida; East Brunswick, New Jersey; and Lake Success, New York.